Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease

Molecular Genetics and Metabolism Reports

Volumn 1, Issue , 2014, Pages 446-450

  Sun, Baodong ^a   Banugaria, Suhrad G ^a   Prater, Sean N ^a   Patel, Trusha T ^a   Fredrickson, Keri ^a   Ringler, Douglas J ^b   De Fougerolles, Antonin ^b   Rosenberg, Amy S ^c   Waldmann, Herman ^d   Kishnani, Priya S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Tolerx Inc   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti CD4 antibody; Antigen specific immune tolerance; Enzyme replacement therapy; Pompe disease

Indexed keywords

DIPHENHYDRAMINE; METHOTREXATE; OKT 4; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; ENZYME REPLACEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TREATMENT OUTCOME;

MURINAE;

EID: 84916603606     PISSN: None     EISSN: 22144269     Source Type: Journal    
DOI: 10.1016/j.ymgmr.2014.08.005     Document Type: Article

References (27)

1. R. Hirschhorn, A.J.J. Reuser, Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency, in: D. Valle, C.R. Scriver (Eds.), Scriver's OMMBID the Online Metabolic & Molecular Bases of Inherited Disease, McGraw-Hill, New York, 2009.
2. P.S. Kishnani, W.L. Hwu, H. Mandel, M. Nicolino, F. Yong, D. Corzo, A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease, J. Pediatr. 148 (2006) 671-676.
3. H.M. van den Hout, W. Hop, O.P. van Diggelen, J.A. Smeitink, G.P. Smit, B.T. Poll-The, H.D. Bakker, M.C. Loonen, J.B. de Klerk, A.J. Reuser, A.T. van der Ploeg, The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature, Pediatrics 112 (2003) 332-340.
4. P.S. Kishnani, D. Corzo, N.D. Leslie, D. Gruskin, A. Van der Ploeg, J.P. Clancy, R. Parini, G. Morin, M. Beck, M.S. Bauer, M. Jokic, C.E. Tsai, B.W. Tsai, C. Morgan, T. O'Meara, S. Richards, E.C. Tsao, H. Mandel, Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease, Pediatr. Res. 66 (2009) 329-335.
5. P.S. Kishnani, D. Corzo, M. Nicolino, B. Byrne, H. Mandel, W.L. Hwu, N. Leslie, J. Levine, C. Spencer, M. McDonald, J. Li, J. Dumontier, M. Halberthal, Y.H. Chien, R. Hopkin, S. Vijayaraghavan, D. Gruskin, D. Bartholomew, A. van der Ploeg, J.P. Clancy, R. Parini, G. Morin, M. Beck, G.S. De la Gastine, M. Jokic, B. Thurberg, S. Richards, D. Bali, M. Davison, M.A. Worden, Y.T. Chen, J.E. Wraith, Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease, Neurology 68 (2007) 99-109.
6. M. Nicolino, B. Byrne, J.E. Wraith, N. Leslie, H. Mandel, D.R. Freyer, G.L. Arnold, E.K. Pivnick, C.J. Ottinger, P.H. Robinson, J.C. Loo, M. Smitka, P. Jardine, L. Tato, B. Chabrol, S. McCandless, S. Kimura, L. Mehta, D. Bali, A. Skrinar, C. Morgan, L. Rangachari, D. Corzo, P.S. Kishnani, Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease, Genet. Med. 11 (2009) 210-219.
7. S.G. Banugaria, S.N. Prater, Y.K. Ng, J.A. Kobori, R.S. Finkel, R.L. Ladda, Y.T. Chen, A.S. Rosenberg, P.S. Kishnani, The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease, Genet. Med. 13 (2011) 729-736.
8. P.S. Kishnani, P.C. Goldenberg, S.L. DeArmey, J. Heller, D. Benjamin, S. Young, D. Bali, S.A. Smith, J.S. Li, H. Mandel, D. Koeberl, A. Rosenberg, Y.T. Chen, Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants, Mol. Genet. Metab. 99 (2010) 26-33.
9. N.J. Mendelsohn, Y.H. Messinger, A.S. Rosenberg, P.S. Kishnani, Elimination of antibodies to recombinant enzyme in Pompe's disease, N. Engl. J. Med. 360 (2009) 194-195.
10. Y.H. Messinger, N.J. Mendelsohn, W. Rhead, D. Dimmock, E. Hershkovitz, M. Champion, S.A. Jones, R. Olson, A. White, C. Wells, D. Bali, L.E. Case, S.P. Young, A.S. Rosenberg, P.S. Kishnani, Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease, Genet. Med. 14 (2012) 135-142.
11. M.E. Elder, S. Nayak, S.W. Collins, L.A. Lawson, J.S. Kelley, R.W. Herzog, R.F. Modica, J. Lew, R.M. Lawrence, B.J. Byrne, B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease, J. Pediatr. 163 (2013) 847-854 (e841).
12. S.G. Banugaria, T.T. Patel, P.S. Kishnani, Immune modulation in Pompe disease treated with enzyme replacement therapy, Expert. Rev. Clin. Immunol. 8 (2012) 497-499.
13. H. Waldmann, Manipulation of T-cell responses with monoclonal antibodies, Annu. Rev. Immunol. 7 (1989) 407-444.
14. S.X. Qin, M. Wise, S.P. Cobbold, L. Leong, Y.C. Kong, J.R. Parnes, H. Waldmann, Induction of tolerance in peripheral T cells with monoclonal antibodies, Eur. J. Immunol. 20 (1990) 2737-2745.
15. N. Salooja, G. Kemball-Cook, E.G. Tuddenham, J. Dyson, Use of a non-depleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX, Br. J. Haematol. 118 (2002) 839-842.
16. N. Raben, K. Nagaraju, E. Lee, P. Kessler, B. Byrne, L. Lee, M. LaMarca, C. King, J. Ward, B. Sauer, P. Plotz, Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II, J. Biol. Chem. 273 (1998) 19086-19092.
17. A. Joseph, K. Munroe, M. Housman, R. Garman, S. Richards, Immune tolerance induction to enzyme-replacement therapy by coadministration of short-term, low-dose methotrexate in a murine Pompe disease model, Clin. Exp. Immunol. 152 (2008) 138-146.
18. B. Sun, A. Bird, S.P. Young, P.S. Kishnani, Y.T. Chen, D.D. Koeberl, Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance, Am. J. Hum. Genet. 81 (2007) 1042-1049.
19. A. Amalfitano, A.R. Bengur, R.P. Morse, J.M. Majure, L.E. Case, D.L. Veerling, J. Mackey, P. Kishnani, W. Smith, A. McVie-Wylie, J.A. Sullivan, G.E. Hoganson, J.A. Phillips III, G.B. Schaefer, J. Charrow, R.E. Ware, E.H. Bossen, Y.T. Chen, Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial, Genet. Med. 3 (2001) 132-138.
20. M.A. Abbott, S.N. Prater, S.G. Banugaria, S.M. Richards, S.P. Young, A.S. Rosenberg, P.S. Kishnani, Atypical immunologic response in a patient with CRIM-negative Pompe disease, Mol. Genet. Metab. 104 (2011) 583-586.
21. T.E. Hunley, D. Corzo, M. Dudek, P. Kishnani, A. Amalfitano, Y.T. Chen, S.M. Richards, J.A. Phillips III, A.B. Fogo, G.E. Tiller, Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease, Pediatrics 114 (2004) e532-e535.
22. S.G. Banugaria, T.T. Patel, J. Mackey, S. Das, A. Amalfitano, A.S. Rosenberg, J. Charrow, Y.T. Chen, P.S. Kishnani, Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells, Mol. Genet. Metab. 105 (2012) 677-680.
23. D. Winsor-Hines, C. Merrill, M. O'Mahony, P.E. Rao, S.P. Cobbold, H. Waldmann, D.J. Ringler, P.D. Ponath, Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody, J. Immunol. 173 (2004) 4715-4723.
24. C.M. Ng, E. Stefanich, B.S. Anand, P.J. Fielder, L. Vaickus, Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers, Pharm. Res. 23 (2006) 95-103.
25. A.B. Gottlieb, M. Lebwohl, S. Shirin, A. Sherr, P. Gilleaudeau, G. Singer, G. Solodkina, R. Grossman, E. Gisoldi, S. Phillips, H.M. Neisler, J.G. Krueger, Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study, J. Am. Acad. Dermatol. 43 (2000) 595-604.
26. S. Qin, S.P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, H. Waldmann, "Infectious" transplantation tolerance, Science 259 (1993) 974-977.
27. V.G. Oliveira, A. Agua-Doce, M.A. Curotto de Lafaille, J.J. Lafaille, L. Graca, Adjuvant facilitates tolerance induction to factor VIII in hemophilic mice through a Foxp3-independent mechanism that relies on IL-10, Blood 121 (2013) 3936-3945 (S3931).